Clinical trial · Interventional
Genetic Characteristics of Metastatic Breast Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Genomic analysis for metastatic breast cancer(MBC) patients * Participant (Inclusion criteria) 1. Patients who diagnosed metastatic/stage IV breast cancer 2. Patients who were not received treatment for metastatic breast cancer on palliative setting * Process (1) Tissue/ Blood sample * At diagnosis, MBC tissue / blood sample (20cc) will be obtained. * At disease progression after 1st line treatment for MBC, blood sample (20cc) will be obtained (tissue; optional) (2) WES, RNASeq, ctDNA, Exosome * We will analyze genomic characteritics using WES, RNASeq, ctDNA, Exosome.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Genomic analysis | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Metastatic breast cancer cohort
- description
- Metastatic breast cancer with genetic tests including WES, RNASeq, ctDNA and exosome
- interventionNames
- Diagnostic Test: Genomic analysis
Primary outcomes (1)
- measure
- Genomic profiling of MBC patients
- timeFrame
- 60 months
- description
- Gemetic alteration frequency, the association between genetic alteration and survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who diagnosed ad metastatic breast cancer * Patients who were not received treatment on palliative setting Exclusion Criteria: * Patients who did not agree this study * Patients who did not have any pathologic specimen at MBC diagnosis.
References
Publications (0)
Data not yet available